Personalmatsalen Active Biotech is a corporate office located in Lund, specializing in the development of new treatments for cancer and inflammatory eye diseases. The organization is engaged in research and development within the biopharmaceutical sector, focusing on innovative therapeutic approaches that modulate the immune system. Active Biotech has been granted a patent for its tasquinimod formulation in the United States, which is a significant aspect of its product pipeline.
The company has published positive preclinical data regarding tasquinimod's efficacy in treating myelofibrosis, highlighting its commitment to advancing treatment options in this area. In addition to its research initiatives, Active Biotech provides investor relations information and is actively involved in rights issues to engage investors. The organization also hosts extraordinary general meetings and participates in major medical presentations, including the upcoming ASH 2025 and FLORetina 2025 conferences, showcasing its ongoing contributions to the medical and scientific communities.